Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… Board with Leaders in Inherited Retinal Disease and RNA Therapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … of leading experts in inherited retinal disease and RNA therapies,” said Daniel A. de Boer, Chief Executive …
… Always excited about RNA therapies He is one of the founders of ProQR, but even … that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he … as they say. Gerard Platenburg What made you pursue RNA therapy as a potential treatment for these diseases? …
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … Board (SAB) with leaders in inherited retinal disease and RNA therapy. The SAB members are: James Shannon, MD, Chair of …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … Board (SAB) with leaders in inherited retinal disease and RNA therapy. In February, ProQR announced its participation …
